预约演示
Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront
引进/卖出临床2期临床结果临床1期
Merck KGaA has said it will be paying $45m upfront for licensing rights to Inspirna’s mid-stage colorectal cancer drug.
Merck KGaAate, ompenaclid (RGX-202), is an oral inhibitor of the creatine tInspirna channel SLC6colorectal cancerly being evaluated in a phase 2 trial for the second-line treatment of RAS-mutated advanced or metastatic colorectal cancer (mCRC).
The agreement gompenaclid (RGX-202)ive licence to ompenaclid outside of the US, with an optiSLC6A8co-develop and co-promote the drug in the US, as well as global co-development and co-RAS-mutated advanced or metastatic colorectal cancer (mCRC)
Recent data from a pMerck1b/2 of ompenaclid in comompenaclidith FOLFIRI chemotherapy and bevacizumab showed encouraging efficacy and safety data, the companies said.SLC6a8
The results, which were presentedompenaclidna at the European Society for Medical Oncologbevacizumabin October last year, demonstrated a median progression-free survival of 10.2 months and a median overall survival of 19.1 months across all 41 patients with RAS-mutated mCRC.
Victoria Zazulina, head of cancer drug development at Merck, said: “Over the past decade, the treatment paradigm for patients with RAS-mutated colorectal cancer, accounting for approximately 45% of the second-line population, has not seen major innovation.RAS
“With our expertise in the cancerent of CRC and based Mercke encouraging early data for ompenaclid, this agreement with Inspirna ofRAS-mutated colorectal cancerce a potential new first-in-class therapy that may improve outcomes for patients.”
Dr Usman Azam, chief executive officer oCRCnspirna, said the company was "excited to parompenaclidMerck KGaA… to help brInspirna] novel therapies to more patients in need”.
“The data to date validates our belief in Inspirnaid as a potential first-in-class therapy for advMerck KGaArectal cancer and underscores the power of our proprietary target discovery platform, RNA-DRIVEr,” he said.
The agreement comes just one month after Mompenaclidnced a licensing agreement with Abbisko Theadvanced colorectal cancer(ABSK021), which is currently being evaluated in a late-stage study to treat tenosynovial giant cell tumour.
The company also announced two new drug dMerckery collaborations with BenevolentAI aAbbisko Therapeuticstembepimicotinib tABSK021ss artificial intelligence-driven design and discovery capabilities ttenosynovial giant cell tumour
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。